181 related articles for article (PubMed ID: 17621880)
1. Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas.
Urosevic M
Curr Opin Investig Drugs; 2007 Jun; 8(6):493-8. PubMed ID: 17621880
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
Zhao P; Zhu YH; Wu JX; Liu RY; Zhu XY; Xiao X; Li HL; Huang BJ; Xie FJ; Chen JM; Ke ML; Huang W
Life Sci; 2007 Aug; 81(9):695-701. PubMed ID: 17714738
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the management of cutaneous lymphomas.
Belloni B; Johansen N; Glass LF; Dummer R
Semin Oncol; 2012 Apr; 39(2):150-62. PubMed ID: 22484187
[TBL] [Abstract][Full Text] [Related]
5. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
6. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.
Urosevic M; Fujii K; Calmels B; Laine E; Kobert N; Acres B; Dummer R
J Clin Invest; 2007 Oct; 117(10):2834-46. PubMed ID: 17823660
[TBL] [Abstract][Full Text] [Related]
7. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
8. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
9. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
10. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs in cutaneous T-cell lymphomas.
Dummer R
Expert Opin Emerg Drugs; 2005 May; 10(2):381-92. PubMed ID: 15934873
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
13. Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.
Aldaoud A
Dermatol Clin; 2008 Jan; 26 Suppl 1():15-7. PubMed ID: 18405181
[No Abstract] [Full Text] [Related]
14. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
15. TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial.
Dreno B; Urosevic-Maiwald M; Kim Y; Guitart J; Duvic M; Dereure O; Khammari A; Knol AC; Derbij A; Lusky M; Didillon I; Santoni AM; Acres B; Bataille V; Chenard MP; Bleuzen P; Limacher JM; Dummer R
PLoS One; 2014; 9(2):e83670. PubMed ID: 24586226
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphoma.
Gemmill R
Semin Oncol Nurs; 2006 May; 22(2):90-6. PubMed ID: 16720231
[TBL] [Abstract][Full Text] [Related]
17. Standard and experimental therapy in cutaneous T-cell lymphomas.
Dummer R; Cozzio A; Meier S; Beyeler M; Laetsch B; Doebbeling U; Urosevic M
J Cutan Pathol; 2006 Feb; 33 Suppl 1():52-7. PubMed ID: 16412213
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
Stadler R; Kremer A
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
[TBL] [Abstract][Full Text] [Related]
19. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
20. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.
Foss F; Duvic M; Olsen EA
Am J Hematol; 2011 Jul; 86(7):627-30. PubMed ID: 21674574
[No Abstract] [Full Text] [Related]
[Next] [New Search]